IBIO
iBio, Inc.Company Information
- Company Name
- iBio, Inc.
- CIK
- CIK0001420720
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- IBIO: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-26
- Last sale
- 2023-11-01
- Shares purchased (TTM)
- 51,105
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 34,740,161
- Shares outstanding
- 104,060,000
- Ownership
- 33.38%
Earnings Market Reaction
- Filing date
- 2026-08-28
- Price on filing date
- —
- 1-month reaction
- -5.88%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 56 | 48 | 29 | 28 | 9 | 5 | 7 | 11 | 14 | 5 | 3 | 1 | ||||||
| Restricted Cash Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 3 | ||||||
| Notes And Loans Receivable Net Current | - | - | - | - | - | - | - | - | 1 | - | - | - | ||||||
| Common Stock Share Subscribed But Unissued Subscriptions Receivable | - | - | - | - | 0 | - | 0 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | - | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Debt Securities Current | - | 27 | 24 | 21 | - | - | - | - | - | - | - | - | ||||||
| Available For Sale Securities Debt Securities Current | 32 | 27 | 24 | 21 | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | - | - | - | - | 15 | 15 | 18 | ||||||
| Assets Current | 92 | 77 | 53 | 51 | 10 | 6 | 8 | 12 | 16 | 36 | 20 | 23 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Right Of Use Asset | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes And Loans Receivable Net Noncurrent | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 4 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | ||||||
| Prepaid Expense Noncurrent | 0 | 0 | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Security Deposit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 99 | 86 | 64 | 64 | 23 | 19 | 22 | 25 | 29 | 50 | 34 | 38 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | ||||||
| Accrued Liabilities Current | 6 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 4 | 4 | 3 | ||||||
| Finance Lease Liability Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Secured Debt Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Notes Payable Current | - | - | - | 1 | 1 | 1 | 0 | 0 | 0 | 13 | 13 | 13 | ||||||
| Short Term Non Bank Loans And Notes Payable | - | - | - | - | - | 0 | 1 | - | 0 | - | - | - | ||||||
| Contract With Customer Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | - | - | ||||||
| Liabilities Current | 12 | 7 | 6 | 6 | 6 | 5 | 5 | 3 | 4 | 21 | 22 | 21 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Secured Long Term Debt | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Liabilities | 13 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 25 | 25 | 24 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | 1 | 1 | 1 | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 451 | 432 | 403 | 394 | 347 | 338 | 336 | 336 | 335 | 331 | 312 | 308 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | -0 | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -365 | -355 | -347 | -338 | -332 | -327 | -322 | -318 | -314 | -306 | -303 | -295 | ||||||
| Stockholders Equity | 86 | 78 | 57 | 56 | 15 | 11 | 14 | 18 | 21 | 25 | 9 | 13 | ||||||
| Liabilities And Stockholders Equity | 99 | 86 | 64 | 64 | 23 | 19 | 22 | 25 | 29 | 50 | 34 | 38 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | - | ||||||
| Debt Securities Available For Sale Amortized Cost Current | 32 | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | ||||||
| Common Stock Shares Issued | 56 | 35 | 30 | 20 | 19 | 10 | 9 | 9 | 9 | 9 | 3 | 1 | ||||||
| Shares Outstanding | 56 | 35 | 30 | 20 | 19 | 10 | 9 | 9 | 9 | 9 | 3 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialiBio, Inc. (IBIO) — SEC Financial Statements & Analysis
iBio, Inc. (IBIO) is a pharmaceutical preparations company, incorporated in DE. iBio, Inc. trades on Nasdaq as: IBIO. iBio, Inc. (IBIO)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-08-28. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), iBio, Inc. carries a market cap of $182.10M, a P/E ratio of -5.51x, a P/B ratio of 2.12x, a P/S ratio of 1821.05x, an enterprise value of $125.48M, and an EV/EBITDA multiple of -3.63x. On profitability, it posts an operating margin of -35141.00%, a net margin of -33044.00%, a Return on Equity (ROE) of -65.70%, a Return on Assets (ROA) of -54.04%, and a Return on Invested Capital (ROIC) of -194.84%. Per share, it reports EPS of $-0.32, diluted EPS of $-0.32, free cash flow per share of $-0.23, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -75.00% year-over-year, net income growth of 79.81% year-over-year, and EPS growth of -81.86% year-over-year. On the balance sheet, it maintains a current ratio of 7.85x, a quick ratio of 7.59x, working capital of $80.48M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, an interest coverage ratio of -242.35x, free cash flow of $-23.80M (TTM), and net debt of $-56.62M. Figures sourced from SEC EDGAR.
- Market Cap
- $182.10M
- P/E TTM
- -5.51x
- EPS TTM
- $-0.32
- P/B TTM
- 2.12x
- ROE TTM
- -65.70%
- ROA TTM
- -54.04%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-23.80M
- Net Revenue TTM Growth 1Y
- -75.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is iBio, Inc. in?
iBio, Inc. (IBIO) operates in the Pharmaceutical Preparations industry.
What exchange does IBIO trade on?
iBio, Inc. (IBIO) trades on the Nasdaq.
Where is iBio, Inc. incorporated?
iBio, Inc. is incorporated in DE.
When was iBio, Inc. (IBIO)'s most recent SEC filing?
iBio, Inc. (IBIO)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-08-28.
What is IBIO's market cap?
iBio, Inc. (IBIO) has a market capitalization of $182.10M as of 2026-06-30.
What is IBIO's EPS (earnings per share)?
iBio, Inc. (IBIO)'s trailing twelve month EPS is $-0.32 as of 2026-06-30.
What is IBIO's ROE (return on equity)?
iBio, Inc. (IBIO)'s trailing twelve month Return on Equity (ROE) is -65.70% as of 2026-06-30.
What is IBIO's ROA (return on assets)?
iBio, Inc. (IBIO)'s trailing twelve month Return on Assets (ROA) is -54.04% as of 2026-06-30.
What is IBIO's ROIC (return on invested capital)?
iBio, Inc. (IBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -194.84% as of 2026-06-30.
What is IBIO's EV/EBITDA?
iBio, Inc. (IBIO)'s trailing twelve month EV/EBITDA is -3.63x as of 2026-06-30.